Companion Diagnostics Market

According to Stratistics MRC, the Global Companion Diagnostics Market is accounted for $10.4 billion in 2026 and is expected to reach $30.1 billion by 2034 growing at a CAGR of 14.2% during the forecast period. Companion diagnostics are medical devices or tests that provide essential information about the safety and effectiveness of a corresponding drug or biological product, enabling healthcare providers to determine whether a particular therapeutic treatment is appropriate for an individual patient. These tests identify specific biomarkers, genetic mutations, or protein expressions that predict treatment response. The growing emphasis on precision medicine and targeted therapies is transforming oncology and other therapeutic areas, making companion diagnostics an integral component of modern drug development and clinical practice worldwide.

Market Dynamics:

Driver:

Rising prevalence of cancer and chronic diseases

The global burden of cancer and chronic conditions continues to escalate, creating urgent demand for targeted therapies paired with companion diagnostics that optimize treatment selection. Oncology remains the dominant application area, with companion tests identifying patients likely to respond to specific immunotherapies or kinase inhibitors, thereby avoiding unnecessary side effects and healthcare costs. As chronic diseases become increasingly complex, one-size-fits-all approaches are giving way to biomarker-driven strategies. This shift is compelling pharmaceutical companies to develop companion diagnostics alongside novel therapeutics, driving market expansion as regulatory agencies increasingly require such tests for approval of precision medicines.

Restraint:

High development costs and regulatory complexities

Developing and commercializing companion diagnostics involves substantial financial investment and navigating intricate regulatory pathways that delay market entry. Manufacturers must simultaneously validate their test with the corresponding drug, requiring coordinated clinical trials and demonstrating both analytical and clinical utility. Different regulatory frameworks across regions, such as FDA and EMA requirements, create additional compliance burdens and increase time-to-market. Smaller diagnostic companies often lack resources to meet these demands, limiting competition and innovation. These challenges result in higher product costs, which are eventually passed to healthcare systems, potentially restricting patient access despite clear clinical benefits.

Opportunity:

Liquid biopsy advancements for non-invasive testing

Emerging liquid biopsy technologies are creating significant opportunities by enabling companion diagnostic testing from simple blood draws instead of invasive tissue biopsies. This approach captures circulating tumor DNA and other biomarkers, allowing real-time monitoring of treatment response and detection of resistance mutations without repeated surgical procedures. Liquid biopsies are particularly valuable for hard-to-access tumors and for patients too ill for traditional biopsies. As sensitivity and specificity continue to improve, these tests are expanding companion diagnostics into new applications, including early cancer detection and minimal residual disease monitoring, opening substantial revenue streams beyond conventional treatment selection.

Threat:

Reimbursement uncertainties across healthcare systems

Inconsistent and evolving reimbursement policies pose a serious threat to widespread adoption of companion diagnostics, as payers may not cover tests lacking clear economic evidence. While regulators increasingly mandate companion diagnostics for certain drugs, reimbursement decisions often lag behind, creating market access gaps. Private insurers and public healthcare systems evaluate the cost-effectiveness of testing differently, leading to geographic disparities in patient access. The rapid pace of biomarker discovery outstrips the ability of health technology assessment bodies to establish coverage policies, causing treatment delays for patients awaiting test results. These uncertainties discourage investment in test development.

Covid-19 Impact:

The COVID-19 pandemic had a dual impact on the companion diagnostics market, initially disrupting clinical trials and non-urgent testing while later accelerating precision medicine adoption. Laboratory shutdowns and redeployment of resources toward COVID-19 testing delayed companion diagnostic development programs and reduced patient access to routine cancer testing. However, the pandemic also demonstrated the power of rapid molecular diagnostics and decentralized testing models, driving investment in platforms applicable to companion testing. Increased awareness of personalized approaches to healthcare, combined with telemedicine expansion and home-based sample collection, has created lasting infrastructure improvements that benefit companion diagnostics adoption in the post-pandemic era.

The Tissue Samples segment is expected to be the largest during the forecast period

The Tissue Samples segment is expected to account for the largest market share during the forecast period, reflecting the longstanding gold standard status of tissue biopsies for biomarker analysis. Formalin-fixed paraffin-embedded tissue blocks remain the preferred sample type for immunohistochemistry and next-generation sequencing-based companion tests, particularly in oncology where tumor architecture and cellular context are critical. Major pharmaceutical companies have validated numerous tissue-based companion diagnostics for drugs targeting solid tumors, including lung, breast, and colorectal cancers. The extensive installed base of pathology laboratories and established reimbursement pathways for tissue testing further reinforce this segment's dominance throughout the forecast timeline.

The Personalized Treatment Selection segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Personalized Treatment Selection segment is predicted to witness the highest growth rate, driven by the expanding arsenal of targeted therapies across multiple disease areas beyond oncology. This application directly matches patients with the most effective drug based on their unique biomarker profile, minimizing trial-and-error prescribing and adverse events. Advances in multi-omics technologies enable simultaneous assessment of hundreds of biomarkers, allowing comprehensive treatment algorithms. Pharmaceutical companies increasingly structure drug development programs around companion diagnostics that prospectively identify responsive patient populations, accelerating regulatory approval and market adoption. As precision medicine penetrates cardiology, neurology, and infectious diseases, personalized treatment selection becomes the fastest-growing application.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by robust healthcare infrastructure, high pharmaceutical R&D spending, and favorable regulatory frameworks. The United States leads in companion diagnostic approvals through the FDA's simultaneous review process alongside drug approvals, creating a streamlined pathway for market entry. Strong reimbursement coverage from public and private payers, combined with widespread adoption of genomic testing in clinical practice, drives utilization. Major diagnostic manufacturers and pharmaceutical companies headquartered in the region continuously invest in novel biomarker discovery and test development. Patient awareness of precision medicine benefits further accelerates North American market dominance throughout the forecast period.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, propelled by rapidly improving healthcare systems, large patient populations, and increasing government investments in precision medicine initiatives. Countries including China, Japan, India, and South Korea are expanding molecular diagnostics infrastructure and implementing national genomic medicine programs. Rising prevalence of cancer and chronic diseases, coupled with growing pharmaceutical industry presence in the region, creates substantial demand for companion diagnostic testing. Lower labor and operational costs for clinical trials attract international sponsors, further integrating Asia Pacific into global drug development networks. As regulatory harmonization progresses and healthcare spending increases, this region emerges as the fastest-growing market for companion diagnostics.
 
Key players in the market

Some of the key players in Companion Diagnostics Market include F Hoffmann La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Agilent Technologies Inc., Qiagen NV, Illumina Inc., Danaher Corporation, BioMerieux SA, Siemens Healthineers AG, Myriad Genetics Inc., Guardant Health Inc., Exact Sciences Corporation, Foundation Medicine Inc., Sysmex Corporation and Bio Rad Laboratories Inc.

Key Developments:

In March 2026, Roche announced the expansion of its digital pathology portfolio, integrating AI-driven algorithms to enhance the accuracy of HER2 and PD-L1 biomarker interpretation in oncology, supporting its market-leading companion diagnostics on the VENTANA platform.

In March 2026, Abbott announced that its acquisition of Exact Sciences, valued at over $30 billion, is on track to close in Q2 2026. This move integrates market-leading precision oncology diagnostics (Cologuard and Oncotype DX) into Abbott’s portfolio.

In August 2025, Thermo Fisher received CE-IVDR certification for its Oncomine Dx Target Test, expanding its use in Europe to aid in the selection of therapies for patients with advanced non-small cell lung cancer (NSCLC) and cholangiocarcinoma.

Product & Services Covered:
• Product
• Services

Technologies Covered:
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Immunohistochemistry (IHC)
• In Situ Hybridization (ISH)
• Microarrays
• Digital PCR
• Other Emerging Technologies

Indications Covered:
• Oncology
• Cardiovascular Diseases
• Neurological Disorders
• Infectious Diseases
• Autoimmune & Inflammatory Diseases
• Other Indications

Sample Types Covered:
• Tissue Samples
• Blood Samples (Liquid Biopsy)
• Saliva Samples
• Urine Samples
• Other Sample Types

Applications Covered:
• Patient Stratification
• Drug Efficacy Monitoring
• Safety & Toxicity Profiling
• Biomarker Identification
• Personalized Treatment Selection

End Users Covered:
• Hospitals
• Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Other End Users

Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific   
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
§ Saudi Arabia
§ United Arab Emirates
§ Qatar
§ Israel
§ Rest of Middle East
o Africa
§ South Africa
§ Egypt
§ Morocco
§ Rest of Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances